Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | $750.0M | $909.3M | $743.4M | $1,388.7M | $2,135.9M | $2,300.1M | $2,804.1M | $3,361.9M | $3,202.5M | $3,962.8M | $4,872.1M | $4,743.4M | $5,949.1M | $4,934.1M | $5,099.3M | $5,323.8M | $4,568.6M | $7,567.5M | $9,071.3M | $10.1B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Novo Nordisk A/S's last 12-month Free Cash Flow is $9,793.1M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Novo Nordisk A/S's Free Cash Flow growth was (12.1%). The average annual Free Cash Flow growth rates for Novo Nordisk A/S have been 25.9% over the past three years, 12.0% over the past five years.
Over the last year, Novo Nordisk A/S's Free Cash Flow growth was (12.1%), which is lower than industry growth of (0.1%). It indicates that Novo Nordisk A/S's Free Cash Flow growth is Bad.